EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species

Sevan N Alwan iD, Alexander B Taylor iD, Stanton F McHardy iD, Michael D Cameron iD, Philip T LoVerde

Pharmaceutics · 27.09.2025 · 17 (10) · 1268

DOI: 10.3390/pharmaceutics17101268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 27.09.2025. Verfasst von Sevan N Alwan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Structural Biology, University of Texas Health at San Antonio, San Antonio, TX 78229, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NIAID, NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schistosomiasis, a neglected tropical disease affecting over 250 million people worldwide, relies on praziquantel (PZQ) as its sole treatment. However, PZQ has significant limitations, including inactivity against juvenile worms, inability to prevent reinfection, and emerging drug resistance. In this review, we outline the development of CIDD-0150303, a novel oxamniquine (OXA) derivative with pan-species and pan-stage activity against Schistosoma mansoni, PZQ-resistant S. mansoni, and S. haematobium. Using a structure-guided design approach, over 350 OXA analogs were synthesized and screened to identify leading drug candidate CIDD-0150303. CIDD-0150303 demonstrates 100% lethality in vitro and up to 80% reduction in worm burden in vivo. CIDD-0150303 is effective against both juvenile and adult parasites as well as PZQ-resistant S. mansoni. This compound represents a promising advance in schistosomiasis treatment to address urgent gaps in control/elimination strategies and PZQ resistance. However, dedicated safety and toxicity studies are still ongoing, and additional in vivo validation is required.

Schlagwörter

Stichwörter der Autor:innen

Schistosomadrug discoverydrug resistanceoxamniquine

Autor:innen und Institutionen

  • Department of Biochemistry and Structural Biology, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
  • Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
  • Center for Innovative Drug Discovery, Department of Chemistry, University of Texas at San Antonio, San Antonio, TX 78249, USA.
  • Department of Molecular Medicine, UF Scripps Biomedical Research, Jupiter, FL 33458, USA.

ORCID-Profile: Sevan N Alwan, Alexander B Taylor, Stanton F McHardy, Michael D Cameron

Förderung

  • NIH NIAID
  • NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • Office of the Vice President for Research Internal Funding Programs UT Health San Antoni
  • NCATS NIH HHS
  • Institute for Integration of Medicine and Science (IIMS) at UT Health San Antonio by the National Center for Advancing Translational Sciences, National Institu…
  • Office of the Vice President for Research Internal Funding Programs

Zitieren

APA

Alwan, S. N., Taylor, A. B., McHardy, S. F., Cameron, M. D., & LoVerde, P. T. (2025). Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species. Pharmaceutics, 17(10), 1268. https://doi.org/10.3390/pharmaceutics17101268

Vancouver

Alwan SN, Taylor AB, McHardy SF, Cameron MD, LoVerde PT. Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species. Pharmaceutics. 2025;17(10):1268. doi:10.3390/pharmaceutics17101268

BibTeX
@article{Alwan2025,
  author = {Alwan, Sevan N and Taylor, Alexander B and McHardy, Stanton F and Cameron, Michael D and LoVerde, Philip T},
  title = {Development of a Novel Compound Effective Against Juvenile, Adult, and Drug-Resistant Schistosoma Species},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1268},
  doi = {10.3390/pharmaceutics17101268}
}
Kostenlos starten →